Across all four PDX lines, dasatinib led to decreased phosphorylation levels of SFK substrates, including the well-characterized substrates tensin, annexin, Protein kinase C delta, cub-domain containing protein 1 (CDCP1), and delta-catenin, further supporting dasatinib’s inhibition of SFKs in each tumor. Here, CTNND2 is linked to neoplasm.